BRAIN Biotech AG
Michael Schneiders has a diverse work experience in the financial industry spanning over 20 years. Michael is currently the Chief Financial Officer (CFO) at Brain Biotech AG, a company focused on industrial biotechnology and sustainable production. Prior to this role, they served as the Head of Investor Relations & Sustainability at Brain Biotech AG, and as the Head of Investor Relations at the same company. Before joining Brain Biotech AG, Michael held positions at Pareto Securities, equinet Bank AG, Oddo Seydler, Kepler Cheuvreux, Cheuvreux, Sal. Oppenheim, Citi, and Dresdner Kleinwort Benson, primarily in equity sales.
Michael Schneiders attended Rheingymnasium from 1981 to 1990, where they obtained their Abitur. Michael then pursued Business Administration and Finance at Universität Siegen from 1990 to 1996. Additionally, they studied Economics at the University of Redlands from 1993 to 1994, earning a Bachelor of Science (BS) degree.
This person is not in any offices
BRAIN Biotech AG
BRAIN Biotech AG is a leading European supplier of biobased products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. We focus on the fields of nutrition, health and environment. BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into the segments BioProducts, BioScience and BioIncubator. The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded.